Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized strategies to prevent immunologic failure in multidrug-resistant HIV-1 infection
2004-001827-39Phase 3Terminated
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- Jun 2005
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of lopinavir, ritonavir, tenofovir disoproxil fumarate, efavirenz and nevirapine in human immunodeficiency virus infection (HIV) and multidrug-resistant human immunodeficiency virus infection (MDR-HIV) (3 arms), sponsored by IRCCS Ospedale San Raffaele. Primary endpoint: Prevention of immunologic failure. Started Jun 2005; status: terminated.
02
Drugs
lopinavirritonavirtenofovir disoproxil fumarateefavirenznevirapine
03
Conditions
human immunodeficiency virus infection (HIV)multidrug-resistant human immunodeficiency virus infection (MDR-HIV)
Beyond the preview
Go deeper on 2004-001827-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001827-39.